U.S. markets open in 5 hours 51 minutes
  • S&P Futures

    4,140.00
    -6.25 (-0.15%)
     
  • Dow Futures

    34,121.00
    -62.00 (-0.18%)
     
  • Nasdaq Futures

    13,300.25
    -45.75 (-0.34%)
     
  • Russell 2000 Futures

    2,194.70
    -8.60 (-0.39%)
     
  • Crude Oil

    65.82
    +0.54 (+0.83%)
     
  • Gold

    1,834.20
    -1.90 (-0.10%)
     
  • Silver

    27.58
    -0.09 (-0.31%)
     
  • EUR/USD

    1.2143
    -0.0009 (-0.07%)
     
  • 10-Yr Bond

    1.6240
    0.0000 (0.00%)
     
  • Vix

    22.07
    +2.41 (+12.26%)
     
  • GBP/USD

    1.4142
    -0.0002 (-0.01%)
     
  • USD/JPY

    108.7630
    +0.1430 (+0.13%)
     
  • BTC-USD

    57,132.09
    +1,592.90 (+2.87%)
     
  • CMC Crypto 200

    1,548.11
    +1,305.43 (+537.92%)
     
  • FTSE 100

    6,976.28
    +28.29 (+0.41%)
     
  • Nikkei 225

    28,147.51
    -461.08 (-1.61%)
     

Affimed Stock Jumps After Natural Killer Cells With AFM13 Show Clinical Responses, Minimal Toxicity

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Affimed NV (NASDAQ: AFMD) has announced initial clinical data from an investigator-sponsored study evaluating cord blood-derived natural killer (cbNK) cells pre-complexed with Affimed's innate cell engager (ICE) AFM13 (CD16A/CD30).

  • The trial evaluates the pre-complexing of AFM13 with cbNK cells followed by three weekly infusions of AFM13 monotherapy in adult patients with recurrent/refractory CD30-positive lymphomas.

  • All four patients experienced significant disease reduction, with two complete responses and two partial responses as assessed by the investigator, with an objective response rate of 100%.

  • There were no observed events of cytokine release syndrome, neurotoxicity syndrome, or graft-versus-host disease.

  • The study is continuing enrollment of the second dose cohort.

  • The company will host a conference call/webcast on April 14 at 4:05 p.m. E.T.

  • Price Action: AFMD shares rise 40.8% at $11.05 in the premarket session on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.